Kymera Therapeutics

The First Proof-of-Mechanism in a Randomized, Placebo-controlled Study in Targeted Protein Degradation

Read more

Marking Kymera’s 5-Year Anniversary

Read more

Becoming CEO: The First 18 Months

Read more

IRAKIMiDs: A Single Small Molecule Approach to Developing Dual-Function Degraders for B Cell Lymphoma with Multiple Drivers

Read more

Kymera’s IRAK4 degrader for hidradenitis suppurativa: Hitting an elusive target hard for a hard-to-treat inflammatory disease

Read more

Targeted Protein Degradation Comes of Age (As Featured in LifeSciVC)

Read more

Protein Degradation: New Rules for Drug Discovery

Read more

Going after the “undruggable”: the STAT3 story

Read more